



IFW 1645

P/567-129

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Elias Castanas

Date: May 12, 2006

Serial No.: 10/522,215

Group Art Unit: 1645

Filed: April 7, 2005

Examiner: David Lukton

For: STEROID CONJUGATES, PREPARATION THEREOF AND THE USE THEREOF

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement mailed on April 13, 2006, applicant elects, with traverse, the claims of Group 9, i.e., claims 28-37, 40, 41 and 43, drawn to a method of treating a solid tumor or hematological malignancy, wherein an antiandrogen is not used.

Further to the above, the Office Action further states that, in the event that Group 9 is chosen for initial examination, election of the following additional items is required:

- a) a fully defined conjugate in which it is made clear whether a linker is present, and if so, the point of attachment of the linker to the testosterone. If a linker is not present, the election should make clear the mode of bonding between the testosterone and the albumin;
- b) one of the following: (i) the "CAD" is taxol, or (ii) the "CAD" is taxotere;
- c) one of the following: (i) the composition is detectably labeled, or a compound within the composition is detectably labeled, or (ii) the composition is not detectably labeled, and no compound within the composition is detectably labeled;
- d) the species of mammal from which the albumin has been obtained; and
- e) the route of administration (e.g., oral or intravenous).

In response, applicant elects the particular conjugate set forth in claim 44, i.e., Testosterone3-(O-carboxymethyl)oxime-human serum albumin. Applicant submits that the chemical formula of this conjugate is believed to adequately respond to the Examiner's further request for election of items (a) - (e) noted above. If the Examiner does not agree, he is respectfully requested to indicate to applicant's representative in his next Communication any further election which is required.


CONTINGENT EXTENSION REQUEST

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. § 1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. § 1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 12, 2006:

Mark A. Farley

Name of applicant, assignee or
Registered Representative




Signature

May 12, 2006

Date of Signature

MAF:jl

Respectfully submitted,



Mark A. Farley
Registration No.: 33,170
OSTROLENK, FABER, GERB & SOFFEN, LLP
1180 Avenue of the Americas
New York, New York 10036-8403
Telephone: (212) 382-0700